-
Following disappointing results from the VOICE trial released at the recent 20th Conference on Retroviruses and Opportunistic Infections (CROI) in Atlanta, a new U.S. Women and PrEP Working Group has called on the federal government to help American women use antiretroviral pre-exposure prophylaxis (PrEP) safely and effectively. But the AIDS Healthcare Foundation (AHF) responded by urging the Food and Drug Administration to rescind its approval of Truvada (tenofovir/emtricitabine) for HIV prevention.
3 hours ago | HIVandHepatitis.com
-
We need to design prevention trials that ask, “Is this test product better than nothing?” rather than, “Is this test product better than the best available prevention combination we have?”
15 March 2013 | Poz
-
An HIV prevention strategy in which people at risk of becoming exposed to HIV take antiretroviral drugs to reduce their chance of becoming infected (often referred to as pre-exposure prophylaxis or PrEP), may be a cost-effective method
13 March 2013 | Science Daily
-
The VOICE trial results show that we still have a lot to learn about what women really want and need in HIV prevention. The women in the trial are telling us something that is true for every group at risk for HIV: to help more people avoid infection, we need to offer prevention tools they will actually want, demand and use.
12 March 2013 | Huffington Post
-
Dearly beloved, we gather here to say our goodbyes. For over thirty years, condoms have been our only lifesavers in the face of HIV. But as if we needed any additional evidence of the need to turn the page, it came in the form of a seemingly banal conference presentation this week in Atlanta at the 20th Conference on Retroviruses and Opportunistic Infections.
08 March 2013 | Frontiers LA
-
What happens when access to PrEP is interrupted? Will PrEP prove to have merely delayed HIV acquisition in people at high risk for infection?
07 March 2013 | BETA blog
-
To social scientist Judith D. Auerbach, PhD, a consultant to the NIH Office of AIDS Research and San Francisco AIDS Foundation, the VOICE results raise a number of questions—but not the ones you might think.
06 March 2013 | BETA blog
-
The results were disappointing in every way: the products evaluated were not shown to be effective, the adherence to using the products was dismal – and cancelling the possibility of learning if the products conferred any protection, it was worst among the demographic at highest risk — the younger, unmarried women.
05 March 2013 | Science Speaks
-
Comments on the disappointing vaginal microbicide and PrEP results from AVAC, the Gates Foundation, the NIH, and others.
05 March 2013 | AVAC
-
Demonstration projects are launching across the country and around the world to evaluate how best to make PrEP available in the real world, but another important question is this: What happens when PrEP becomes unavailable to people who are already using it?
05 March 2013 | BETA blog
Get set for HIV treatmentA tool to help you decide whether you are ready to start taking HIV treatment.
HIV, GPs & other primary careThis booklet explains the services GPs offer, how this fits with HIV specialist care, and how to make the most of primary care services.
Treatment as prevention – free webinar 20 March 2013As
part of its European HIV prevention work, NAM is collaborating...
Microbicides research – free webinar 22 February 2013As
part of its European HIV prevention work, NAM is collaborating...
HIV treatment update – Winter 2013 21 February 2013The new edition of HIV treatment update (HTU) is on...